A strong franchise in a tense reset
- PYLARIFY is still the center of the story, with Q1 2026 Oncology revenue of $240.9 million.
- The key debate is whether PYLARIFY TRUVU can restore pricing power after lower net price hurt Q1 sales.
- NEURACEQ gives Lantheus a second growth path in Alzheimer's imaging, with Q1 2026 revenue of $35.4 million.
- DEFINITY remains a steady cardiology product, with Q1 2026 Cardiology revenue of $84.6 million.
- The LNTH-2501 FDA setback adds delay risk, but the main 2027 story still depends on the TRUVU switch.
The 2027 setup got messier
Lantheus is in a transition year. PYLARIFY, its prostate cancer PET imaging agent, is still the main profit pool. But Q1 2026 showed the pressure clearly: PYLARIFY volume increased, while revenue fell because net selling price was lower.
The bull case is simple. PYLARIFY TRUVU is already FDA approved, and management plans the commercial switch to begin in Q4 2026. TRUVU keeps the same diagnostic job as PYLARIFY, but it can support larger manufacturing batch sizes at certain sites. If reimbursement and customer setup go well, 2027 can bring better growth and margin leverage.
NEURACEQ helps bridge the gap. It generated $35.4 million in Q1 2026 and grew 14.3% from Q4 2025, according to management. That gives Lantheus a real neurology leg while Alzheimer's testing demand builds.
The bear case is about execution and timing. The FDA issued a Complete Response Letter for LNTH-2501 in June 2026, meaning it was not approved yet, due to manufacturing-related issues at a third-party facility. That is not the main value driver, but it shows why manufacturing and regulatory follow-through matter so much in this business.
Selling short-lived medical tracers
Lantheus makes money by selling diagnostic agents to radiopharmacies, hospitals, and clinics. These agents are used with imaging machines so doctors can see disease inside the body. PET means positron emission tomography, a scan that uses a small radioactive tracer.
The company has narrowed its focus toward PET radiodiagnostics. It sold its legacy SPECT business effective January 1, 2026, and is looking at value-maximizing alternatives for its radiotherapeutic pipeline. In plain English, it wants more capital and attention on finding disease, not on trying to treat it directly.
The moat is commercial and operational. Lantheus leads in PSMA PET imaging for prostate cancer, has a large production and distribution network, and now has a growing Alzheimer's imaging business. The weak point is that these products need tight manufacturing, isotope supply, payer coverage, and local site readiness.
Four pillars and two options
PYLARIFY
PYLARIFY is the market-leading PSMA-targeted PET imaging agent for prostate cancer. It is still the main revenue driver, but Q1 2026 showed price pressure even as volume increased.
PYLARIFY TRUVU
TRUVU is the newly approved PYLARIFY formulation. Its main promise is better manufacturing output, with the commercial transition planned to start in Q4 2026.
NEURACEQ
NEURACEQ is an F18 PET imaging agent used to show beta-amyloid plaque in Alzheimer's disease. It produced $35.4 million in Q1 2026 revenue and is becoming the second growth engine.
DEFINITY
DEFINITY is an ultrasound-enhancing agent used in cardiology. It is not the flashiest product, but it gives Lantheus a steady base outside oncology.
MK-6240
MK-6240 is a tau-targeted PET diagnostic for Alzheimer's disease. Its FDA action date is August 13, 2026, making it one of the next important pipeline events.
LNTH-2501
LNTH-2501 is a PET imaging kit for certain neuroendocrine tumors. The FDA issued a Complete Response Letter in June 2026 tied to third-party manufacturing conditions, so launch timing is delayed.
PNT2003
PNT2003 is a radioequivalent product for gastroenteropancreatic neuroendocrine tumors. It has tentative approval, but it is not the core near-term thesis.
PYLARIFY still dominates sales
This mix is from Q1 2026, after Lantheus reconfigured reporting around Oncology, Cardiology, Neurology, and Strategic Partnerships and Other. The caveat is concentration: Oncology was about 63.8% of revenue, so PYLARIFY pricing and the TRUVU switch carry outsized weight.
What could break the setup
TRUVU site-by-site launch friction
High impact · Medium oddsPYLARIFY TRUVU has FDA approval, but the commercial job is not done. Lantheus must move customers, radiopharmacies, and reimbursement workflows over in Q4 2026. If sites are not ready, PYLARIFY revenue could be disrupted during the handoff.
PYLARIFY net price erosion
High impact · Medium oddsThe Q1 2026 filing said the PYLARIFY year-over-year decline came from lower net selling price while volume increased. That means demand is not the only issue. If TRUVU cannot improve the economics, 2027 growth may disappoint.
LNTH-2501 manufacturing delay
Medium impact · Medium oddsThe FDA issued a Complete Response Letter for LNTH-2501 in June 2026. The issue was tied to unresolved manufacturing-related conditions at a third-party facility, not a stated safety or efficacy problem. Still, a delayed approval can push out a new revenue stream from the Evergreen deal.
NEURACEQ supply cannot match demand
Medium impact · Medium oddsNEURACEQ is growing quickly, with Q1 2026 revenue up 14.3% from Q4 2025. If Alzheimer's therapy adoption accelerates faster than manufacturing capacity, Lantheus may miss part of the market opportunity. PET tracers are hard to scale because production and delivery timing are tight.
Leadership and portfolio reset risk
Medium impact · Medium oddsManagement has said a new permanent CEO is expected, and the company is reviewing alternatives for therapeutic pipeline assets. That can create a cleaner diagnostics story, but it can also slow decisions. Investors need clarity on what gets sold, kept, or funded.
In one breath
What does Lantheus do?
Lantheus sells medical imaging agents. These products help doctors see prostate cancer, heart function, and signs of Alzheimer's disease using PET scans or ultrasound.
Why is PYLARIFY TRUVU important?
TRUVU is the next version of PYLARIFY, Lantheus's main prostate cancer imaging product. It may improve manufacturing output and help the company reset the economics of the franchise in 2027.
What happened to LNTH-2501?
The FDA issued a Complete Response Letter in June 2026, which means the agency did not approve it yet. The problem was tied to manufacturing conditions at a third-party facility, not a stated concern about safety or efficacy.
Is Lantheus only a cancer imaging company?
No. Oncology is the largest segment, but Lantheus also has Cardiology through DEFINITY and Neurology through NEURACEQ. Neurology is becoming more important as Alzheimer's diagnostic demand grows.